*Mycoplasma pneumoniae* is a common causative pathogen in community-acquired pneumonia (CAP) during childhood. In the post--pneumococcal conjugate vaccine (PCV) 13 era, the epidemiology of pediatric pneumonia has changed. In some countries where PCV13 is already included in national immunization program, *M. pneumoniae* has become the leading pathogen in pediatric CAP ([@R1],[@R2]).

The clinical manifestations of *M. pneumoniae* infection are usually mild and self-limited. However, life-threatening pneumonia or even acute respiratory distress syndrome requiring extracorporeal membrane oxygen has been reported ([@R3]). Furthermore, some extrapulmonary symptoms, such as mucositis, hepatitis, encephalitis, hemolysis, or erythema multiforme, have linked *M. pneumoniae* infection to the formation of autoimmunity or immune complexes. The association between *M. pneumoniae* and refractory asthma has also been mentioned ([@R4]).

Macrolides are the first-line therapy for *M. pneumoniae*. Because of high oral bioavailability and once-daily formulation, macrolides have been widely used in outpatient settings. During the past 10 years, however, macrolide-resistant *Mycoplasma pneumoniae* (MRMP) has emerged worldwide. The most prevalent area is Asia, where prevalence rates are 13.6%--100% ([@R5]). In Japan and China, resistance rates are \>90% in some epidemic years ([@R5],[@R6]).

The treatment of MRMP has become challenging. Although 1 report showed more complications in managing MRMP infections ([@R7]), the association between severe disease and resistance remains inconsistent and unclear. We conducted a systematic review and meta-analysis to examine the effect of macrolide resistance on the manifestations, outcomes, and clinical judgment of *M. pneumoniae* infection.

Methods
=======

Search Strategy
---------------

We conducted a systematic literature search in PubMed, Embase, and the Cochrane Library database using the keywords *Mycoplasma pneumoniae*, macrolide, antibiotic resistance, and drug resistance. There was no language restriction in our search. We reviewed eligible full texts and the reference lists of the relevant studies. The last update of the study was on December 1, 2019.

Two independent reviewers (Y.-C.C. and T.-H.C.) screened all titles and abstracts for eligibility. Studies were eligible for inclusion if the study population was restricted to children (\<18 years of age) with community-acquired pneumonia; macrolide resistance was detected by PCR including the 2 common point mutations, positions 2063 and 2064; and a direct comparator was used in the same cohorts (macrolide-sensitive *M. pneumoniae* \[MSMP\] group). We excluded review articles, editorial comments, case reports, and posters but included correspondence or letters that fulfilled these criteria.

Data Extraction and Quality Assessment
--------------------------------------

After full-text screening for eligibility and review, the 3 authors extracted data independently of one another. We resolved disagreements by consensus or review by another reviewer. We extracted the following variables from each study, if available: author, journal, year of publication, study design, study country, time period, detected point mutations, clinical symptoms, total febrile days, length of hospital stay, defervescence days after macrolide, antibiotic history, laboratory results, and chest radiographic findings. We also extracted pediatric data from studies with both children and adults, if available. We assessed the quality of nonrandomized studies included in the meta-analysis using the Newcastle-Ottawa Scale and excluded articles with poor quality (score 0--3).

Data Analysis
-------------

We used Review Manager software version 5.3 (Cochrane Collaboration, <https://training.cochrane.org>) and Comprehensive Meta-Analysis version 3 (Biostat, <https://www.meta-analysis.com>) for the analysis and conducted meta-analysis when [\>]{.ul}3 studies with available data reported the same outcome. We calculated heterogeneity (*I*^2^) to examine statistical heterogeneity across the included studies. We considered *I*^2^ \>50% and p\<0.05 to indicate substantial heterogeneity. We used random effects models to calculate odds ratios for binary outcomes and mean differences for continuous outcomes. We used Egger precision weighted linear regression tests and funnel plots to test potential publication bias. If publication bias was present, we used the trim-and-fill method and calculated Rosenthal's fail-safe *N* to evaluate the effect.

Results
=======

Study Characteristics
---------------------

We identified 1,100 articles in the initial search ([Figure 1](#F1){ref-type="fig"}). After removing duplicates, we screened 892 articles by titles and abstracts. We excluded obviously irrelevant articles and retrieved the remaining 151 for full text assessment. We then excluded epidemiologic or in vitro studies without clinical data. We included 27 full-text studies in the qualitative synthesis. We identified 3 records through manual search of the reference lists of retrieved articles. Finally, we included 24 full-text articles in the meta-analysis. The studies were conducted in the Asia-Pacific region, except for 1 in Italy. The range of resistance rates was 10%--88%. The A2063G transition mutation was detected in all studies ([Table](#T1){ref-type="table"}).

![Flow diagram of selection process for meta-analysis of macrolide-resistant *Mycoplasma pneumoniae* infections in pediatric community-acquired pneumonia.](20-0017-F1){#F1}

###### Characteristics of the eligible studies of macrolide resistance and *Mycoplasma pneumoniae* infections.

  Author               Study period   Country   Mutations detected       Disease entity   Case no.   Resistance
  -------------------- -------------- --------- ------------------------ ---------------- ---------- ------------
  Chen ([@R8])         2014--2016     China     A2063G, A2064G           CAP, inpatient   136        60%
  Ma ([@R9])           2010--2011     China     A2063G, A1290G           CAP, inpatient   57         63%
  Xin ([@R10])         2004--2005     China     A2063G, A2064G           CAP, inpatient   64         59%
  Yuan ([@R11])        2016           China     A2063G, A2064G, C2617G   CAP, inpatient   120        82%
  Zhou ([@R7])         2009--2010     China     A2063G, A2063T, A2064G   CAP, inpatient   235        88%
  Cheong ([@R12])      2011--2013     HK        A2063G                   CAP, inpatient   93         27%
  Lung ([@R13])        2010--2013     HK        A2063G                   CAP, inpatient   48         71%
  Cardinale ([@R14])   2010           Italy     A2063G, A2064G           CAP, inpatient   46         17%
  Akashi ([@R15])      2016--2017     Japan     A2063G, A2064G           CAP, mixed       222        65%
  Ishiguro ([@R16])    2013--2015     Japan     A2063G                   CAP, mixed       109        54%
  Kawai ([@R17])       2005--2010     Japan     A2063G, A2064G           CAP, mixed       29         72%
  Kawai ([@R18])       2005--2012     Japan     A2063G, A2064G           CAP, mixed       188        80%
  Matsubara ([@R19])   2002--2006     Japan     A2063G, A2064G           CAP, NS          69         32%
  Miyashita ([@R20])   2008--2011     Japan     A2063G, A2064G           CAP, NS          71         59%
  Okada ([@R21])       2011           Japan     A2063G, A2064G           CAP, mixed       202        87%
  Kim JH ([@R22])      2011--2015     Korea     A2063G                   CAP, inpatient   250        74%
  Kim YJ ([@R23])      2010--2015     Korea     A2063G                   CAP, inpatient   107        10%
  Lee ([@R24])         2015           Korea     A2063G                   CAP, mixed       94         13%
  Seo ([@R25])         2011           Korea     A2063G                   CAP, inpatient   95         52%
  Yoo ([@R26])         2011           Korea     A2063G                   CAP, mixed       91         30%
  Yoon ([@R27])        2010--2015     Korea     A2063G                   CAP, inpatient   116        71%
  Wu HM ([@R28])       2011           Taiwan    A2063G                   CAP, inpatient   73         12%
  Wu PS ([@R29])       2010--2011     Taiwan    A2063G                   CAP, inpatient   60         23%
  Yang ([@R30])        2010--2017     Taiwan    A2063G, A2063T, A2064G   CAP, mixed       471        24%

\*CAP, community acquired pneumonia; HK, Hong Kong; NS, not specified.

Effect on Clinical Features and Outcomes
----------------------------------------

The duration of fever was longer in patients with MRMP than in patients with MSMP (mean difference \[MD\] 1.71, 95% CI 1.34--2.09; p\<0.001) ([Figure 2](#F2){ref-type="fig"}). The result was stable and consistent within studies (*I*^2^ = 0%; p = 0.54). MRMP infections were also associated with prolonged hospitalization compared with MSMP infections (MD 1.61, 95% CI 1.08--2.13; p\<0.001) ([Appendix](#SD1){ref-type="local-data"} [Figure 1](#F1){ref-type="fig"}). We found no significant heterogeneity in the studies included (*I*^2^ = 28%; p = 0.18).
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We examined the effect of macrolide resistance on work of breath and extrapulmonary symptoms. We found a slight trend toward MRMP patients with more extensive disease ([Appendix](#SD1){ref-type="local-data"} [Figure 2](#F2){ref-type="fig"}). Nevertheless, we found no difference in clinical features, such as dyspnea (OR 1.71, 95% CI 0.69--4.24; p = 0.24) or extrapulmonary manifestations (OR 1.31, 95% CI 0.85--2.02; p = 0.22), in patients with MRMP infections.

Laboratory Results
------------------

We assessed inflammatory markers commonly examined during *M. pneumoniae* infection ([Appendix](#SD1){ref-type="local-data"} [Figure 3](#F3){ref-type="fig"}). Eleven studies provided data on leukocyte count; we found no significant difference between MRMP and MSMP patients (MD 0.09, 95% CI −0.31 to 0.50; p = 0.65). Nine studies assessed C-reactive protein (mg/L) during infection; again, we found no significant differences between MRMP and MSMP patients (MD −2.79, 95% CI −8.33 to 2.76; p = 0.32).
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Chest Radiographic Findings
---------------------------

We assessed the difference in chest radiographic findings in MRMP and MSMP patients ([Appendix](#SD1){ref-type="local-data"} [Figure 4](#F4){ref-type="fig"}). Neither consolidation ratio (OR 1.06, 95% CI 0.88--1.27; p = 0.52) nor pleural effusion (OR 1.19, 95% CI 0.70--2.03; p = 0.51) was influenced by macrolide resistance.
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Effect on Macrolide Efficacy and Antibiotic Prescription
--------------------------------------------------------

In children with MRMP infection, fever may persist for \>48 hours despite macrolide use. [Figure 3](#F3){ref-type="fig"} illustrates significantly increased odds of poor response to macrolide in patients with MRMP infections (OR 21.24, 95% CI 7.90--57.09; p\<0.001).

Because efficacy of macrolides was reduced in patients with MRMP infections, we further investigated the exact effect of macrolide resistance on defervescence. The pooled results show significantly longer febrile duration (days) after ineffective treatment (MD 2.04, 95% CI 1.40--2.69; p\<0.001). However, we observed an overall low-to-moderate heterogeneity within studies (*I*^2^ = 49%; p = 0.07). Considering different treatment policies (timing to initiate second-line antibiotic or corticosteroid) for *M. pneumoniae* among regions, we performed a subgroup analysis according to country ([Figure 4](#F4){ref-type="fig"}).

During macrolide treatment, some patients with *M. pneumoniae* infection would be switched to other classes of antibiotic drugs, such as the most commonly used fluoroquinolones and tetracyclines, that have different mechanisms of action ([Figure 5](#F5){ref-type="fig"}). Increased proportions of patients were changed to second-line treatment when infected with MRMP (OR 4.42, 95% CI 2.32--8.41; p\<0.001). Subgroup analysis divided by countries reveals that the heterogeneities were still high in Japan and Hong Kong.
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The total duration of antibiotic drug treatment was longer when used to treat MRMP infections than when used to treat MSMP infections (MD 2.93, 95% CI 1.97--3.89; p\<0.001) ([Figure 6](#F6){ref-type="fig"}). There was no substantial heterogeneity (*I*^2^ = 0%; p = 0.48).
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Discussion
==========

This systematic review and meta-analysis summarized currently available studies to compare the difference between MRMP and MSMP infections. The resistance rates varied within the studies, even in the same country ([@R5]). The overall resistance rate in large cohort studies in South Korea and Taiwan ([@R30],[@R31]) increased over time; in contrast, the rate has gradually decreased in Japan since 2012 ([@R32],[@R33]).

We applied multiple molecular methods to explain the spread of MRMP in Asia. Some reports using multilocus variable-number tandem-repeat analysis as the molecular typing method showed that the spread of *M. pneumoniae* seemed to be polyclonal ([@R34],[@R35]). However, 2 recently published reports in South Korea and Japan that used multilocus sequence typing as the diagnostic method revealed that the wide spread of MRMP was associated with clonal expansion of the resistant ST3 clone ([@R31],[@R36]). Whole-genome sequencing might be a better and more comprehensive tool for solving inconsistency and investigating *M. pneumoniae* evolutionary trends in the future.

The clinical manifestations, chest radiographic findings, and laboratory data were not altered by macrolide resistance. Although some studies showed more severe radiological findings ([@R30]) and more complications ([@R7]) after MRMP infections, there appeared to be no significant difference in the pooled data. *M. pneumoniae* presents a unique virulence factor in humans, an ADP-ribosyl transferase known as the community-acquired respiratory distress syndrome toxin (CARDS toxin). Lluch-Senar et al. ([@R37]) performed sequence analysis of the P1 adhesin gene and stated that type 2 strain produced more CARDS toxin. However, Zhao et al. ([@R38]) and Eshaghi et al. ([@R39]) failed to demonstrate this difference between MRMP and MSMP. Currently, no evidence supports the causal relationship between macrolide resistance and disease severity.

The efficacy of macrolide is significantly decreased during MRMP treatment compared to MSMP treatment. The most common point mutation in the domain V 23S rRNA is A2063G, which will cause great MIC increase to all macrolide drugs. Other than A2063G, some studies also reported A2064G mutation, which could result in decreased macrolide affinity and elevation of MIC ([@R21]). Based on these results, we expected to see much longer fever duration from ineffective treatment. However, the pooled data revealed only an interval difference of 1.71 days between fever durations in MRMP and MSMP infections. We further examined the exact days of patients being afebrile after macrolide treatment and the clinical judgment on antibiotic drug use. The study results showed significant heterogeneity.

We then performed subgroup analysis by country. The results reflected different treatment policies among countries, even among institutions. Treatment selection for MRMP might modify the effect of macrolide resistance on clinical course. For instance, a report in South Korea ([@R22]) demonstrated less effect of resistance on macrolide efficacy. The possible reason is that steroids were given to 18.5% of patients with MRMP in this cohort, but not to MSMP patients (3%; p = 0.002). The initiation of corticosteroid treatment is early in South Korea ([@R40]) but reserved for refractory cases in Japan ([@R41]). Another study in China ([@R7]) noted that all patients in the report received only macrolides, given that the antimicrobial drug options are limited for preschool-age children. Therefore, more extrapulmonary complications (encephalitis, myocarditis, or hepatitis) occurred.

To treat or not to treat *M. pneumoniae* is still a dilemma to be resolved. MRMP treatment has raised another problem. Our meta-analysis identified 2 knowledge gaps. The first is the diagnostic gap. Macrolide resistance detection in most institutions relied on in-house PCR. Weighing the costs and benefits, it usually takes time to provide formal reports. Physicians usually base their suspicions of MRMP infections on clinical judgment of patients' response to treatment. In Japan and Taiwan, if fever persists for 48--72 hours after macrolide treatment, second-line antimicrobial drugs, such as fluoroquinolone or tetracycline, would be considered ([@R42],[@R43]). Delayed defervescence of 2 days after macrolide ([Figure 4](#F4){ref-type="fig"}) could be explained by this clinical practice. Timeliness of diagnostic tests after disease onset can be a factor in confirming macrolide resistance. Real-time or point-of-care testing should be used to make the diagnosis more precisely and quickly.

The second challenge is the therapeutic gap. In Japan, the therapeutic efficacy of tosufloxacin and minocycline has been demonstrated in several studies ([@R16],[@R18],[@R21]). However, because of side effects and the development of new resistant strains, empirical treatment for MRMP, especially in endemic areas, is the subject of an ongoing debate. In addition, delayed effective antimicrobial treatment for *M. pneumoniae* has been found to be related to immune reaction, which may lead to prolonged or extrapulmonary disease ([@R30]). Macrolide resistance is one of the significant risk factors for delayed effective treatment. This finding partially explains why patients with MRMP infections showed a trend of more extrapulmonary manifestations or consolidation in 2 studies ([@R7],[@R30]). Some randomized controlled trials indicated a positive effect on early corticosteroid treatment whether or not there was macrolide resistance ([@R44],[@R45]). However, a retrospective study of a large database in Japan did not support this viewpoint ([@R46]). A well-designed randomized trial or meta-analysis should be considered to clarify the role of corticosteroids. In conclusion, the management of *M. pneumoniae* infection might need to be reappraised.

In addition to prolonged clinical courses, our study indicates the effect of macrolide resistance on antibiotic drug consumption and imprecision. Increased macrolide usage in primary healthcare settings, as well as unnecessary and inappropriate prescriptions to treat acute respiratory tract infections, are common in countries in Asia ([@R47]*--*[@R49]). Continuous selective pressure of routinely used antibiotic drugs and high population density can possibly explain the emergence of MRMP. The extent of *M. pneumoniae* simultaneously increased with rising resistance, further resulting in increased consumption of antibiotic drugs. Antibiotic stewardship should be promoted to reduce macrolide resistance.

Our meta-analysis has limitations. First, not all reported mutations (such as C2617G) were described or checked in the included studies. Because positions 2063 and 2064 accounted for most of the mutations and have been reported in all articles included in this analysis, this influence could be minimized. Second, co-infection was not excluded in all studies. The co-infection rate with *M. pneumoniae* is low in some studies ([@R1],[@R12],[@R30]). Nevertheless, how to discriminate between carriage and infection is still a key issue. A combination of PCR and serologic tests, such as measurement of *M. pneumoniae*--specific IgM-secreting cells, would be a better way to determine the role of macrolide resistance in the future ([@R50]). Third, the natural course of MRMP infection is modified because in institutions where physicians are alert to MRMP, second-line therapy or corticosteroids will be administered promptly. Although this bias existed in the initial selection process, it reflected the current clinical practice in MRMP-prevalent areas and the dilemma in management of MRMP.

In summary, our analysis found that MRMP infections are associated with longer febrile duration than MSMP infections. Decreased macrolide efficacy and increased ineffective antimicrobial drug use have also been found. The effect of macrolide resistance on disease severity is inconclusive, and there are still diagnostic and therapeutic gaps in the management of MRMP. Reappraisal of precise diagnostic tools and clearly defined treatment are needed.

###### Appendix

Additional information about the study of macrolide-resistant pediatric *Mycoplasma pneumoniae* infections.
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